Our recognition
Latest stories
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results
- Hikma launches Glucentra® as the first generic semaglutide available to patients in Saudi Arabia Press Release, Product 16 September 2026 Hikma launches Glucentra® as the first generic semaglutide available to patients in Saudi Arabia
- R&D at Hikma | Meet Dima Freihat, helping bring medicines from development to manufacturing Story, Life at Hikma 16 September 2026 R&D at Hikma | Meet Dima Freihat, helping bring medicines from development to manufacturing
- Empowered at Hikma | Meet Ana Catarina Costa, Sr. Manager, Regulatory Affairs, Hikma Portugal Story, Life at Hikma 10 September 2026 Empowered at Hikma | Meet Ana Catarina Costa, Sr. Manager, Regulatory Affairs, Hikma Portugal
- Hikma advances its epinephrine nasal spray with multi-market regulatory filings Press Release, Product 09 September 2026 Hikma advances its epinephrine nasal spray with multi-market regulatory filings
Related content